WHO: Asian Progress On NCDs But Drug Costs Critical
This article was originally published in PharmAsia News
In a new report on non-communicable diseases (NCDs), the World Health Organization (WHO) points to progress in Asia towards overall treatment and policy goals but cautions that much still needs to be done to address sharply rising NCD deaths in the region.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.